Clinical trials: Type 1 Diabetes, completed
Diabetes Mellitus, Type 1
Control-IQ Observational (CLIO) Post-Approval Study
Post-approval 522 study designed to collect primarily safety data on the US FDA-cleared product, t:slim X2 insulin pump with Control-IQ technology (Control-IQ system).
- Trial name
- CLIO (NCT04503174)
- Testing
- t:slim X2 pump with Control-IQ technology
- Where
- United States
- Volunteers
- 3,157 people
- Sponsor
- Tandem Diabetes Care, Inc.
Diabetes Mellitus, Type 1
A Study in Participants With Type 1 Diabetes Mellitus
The purpose of this study is: To compare the blood sugar control of LY2605541 with insulin glargine after 78 weeks of treatment.
- Trial name
- IMAGINE 1 (NCT01481779)
- Testing
- Glargine, LY2605541, Insulin Lispro
- Where
- 51 sites in United States, Austria and 7 more
- Volunteers
- 455 people
- Sponsor
- Eli Lilly and Company
type1diabetes
Accuracy of a Continuous Ketone Monitoring (CKM) System in Individuals With Type 1 Diabetes on Insulin Pump Therapy.
The goal of this 14-day randomized pilot trial is to assess the accuracy of a continuous ketone monitoring (CKM) system when compared to standard point-of-care capillary ketone monitors in individuals with type 1 diabetes on…
- Trial name
- CKM 1 (NCT06420518)
- Testing
- Ketogenic diets, 8-hour insulin-suspension period
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- McGill University
Type 1 Diabetes
Feasibility Studies of Personalized Closed Loop
This is a single arm study comprised of a series of feasibility studies.
- Trial name
- NCT04203823
- Testing
- Cloud-based Digital Twin and Meal Prediction algorithms
- Where
- 12 sites in United States
- Volunteers
- 126 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes, Diabetes Mellitus, Type 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01865279
- Testing
- insulin degludec, isophane human insulin
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics
The aim of this study is to verify whether a significant decrease in glucose levels can be achieved with the HM74A agonist GSK256073 in type 2 diabetic patients.
- Trial name
- NCT01147861
- Testing
- GSK256073
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes
Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes
Type 1 diabetes (T1D) continues to be a disease plagued by hyperglycemia, insulin resistance (IR), and increased cardiovascular disease (CVD) despite advances in insulin delivery and glucose monitoring.
- Trial name
- NCT02544321
- Testing
- Bromocriptine
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis, Diabetes Mellitus Type I
Social Determinants in Chronic Disease in British Columbia
Anyone who practices clinical medicine will understand that socially disadvantaged children will have worse health outcomes, no matter what the underlying condition might be.
- Conditions
- Cystic Fibrosis, Diabetes Mellitus Type I, Chronic Renal Insufficiency
- Trial name
- NCT02203084
- Testing
- Social Determinants Questionnaire
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- University of British Columbia
Maturity-Onset Diabetes of the Young, Type 3
The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea
The most prevalent monogenetic diabetic subtype is named maturity onset diabetes of the young type (MODY3) or hepatocyte nuclear factor 1α (HNF1A)-diabetes.
- Trial name
- HNF1A-Clamp (NCT03081676)
- Testing
- Glimepiride 1Mg Tablet, Glucagon-like Peptide-1, Glucose-Dependent Insulinotropic Polypeptide
- Where
- Denmark
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type1diabetes
Morning Versus Afternoon Aerobic Exercise in Type 1 Diabetes
Aim. To determine whether the need for exogenous carbohydrate supplementation during exercise in type 1 diabetes is lower during morning exercise compared to afternoon exercise, and whether this is associated with greater lipid…
- Trial name
- NCT06115616
- Testing
- Morning exercise, Afternoon exercise
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- University of Aarhus
Diabetes Mellitus, Type 1
Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Function of Patients With Type 1 Diabetes
Background: The aim of the present study was to evaluate the changes in the microvascular density and reactivity in patients with type 1 diabetes (T1D) resulting from low intensity chronic exercise training.
- Trial name
- NCT02441504
- Testing
- Low intensity Exercise
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Cardiologia de Laranjeiras
Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus (T1DM)
Clinical Study: Analysis of Glycemic Control and Satisfaction With a Connected Smart Cap in Patients With Type 1 Diabetes Mellitus
This clinical study evaluates the impact of the Cap INSULCLOCK device on glycemic control, treatment adherence, and patient satisfaction in adults with type 1 diabetes mellitus (T1DM).
- Conditions
- Type 1 Diabetes Mellitus, Type 1 Diabetes Mellitus (T1DM), Diabetes Management
- Trial name
- CAPSDM1 (NCT06845891)
- Testing
- CONNECTED SMART CAP
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Fernando Sebastián Valles
Type 1 Diabetes, Type 2 Diabetes
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
The purpose of this study is to demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring (GM) System interstitial glucose results against Reader capillary Blood Glucose (BG) reference using the Consensus Error…
- Trial name
- NCT02073058
- Testing
- No treatment
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Abbott Diabetes Care
Type 1 Diabetes
Pilot Study of Closed-Loop Glucose Control in People With Type 1 Diabetes (BPK004)
This study plans to link two existing technologies, the insulin pump and the continuous glucose monitor (CGM), to essentially develop an artificial pancreas, i.e., closed-loop.
- Trial name
- NCT00977808
- Testing
- Closed-Loop, Model Predictive Control (MPC), Open-Loop
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Pilot Study of Remote Glucose Monitoring Among Pediatric Patients With Type 1 Diabetes
This project explores the feasibility and utility of remote glucose monitoring for a cohort of children and adolescents with type 1 diabetes (T1D) cared for at UC Davis Health (UCDH).
- Trial name
- NCT04696640
- Testing
- Remote Patient Monitoring
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of California, Davis
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of faster-acting insulin aspart compared to NovoRapid® both in combination with insulin degludec in children and adolescents with type 1…
- Trial name
- onset®7 (NCT02670915)
- Testing
- Faster-acting insulin aspart, insulin aspart, insulin degludec
- Where
- 155 sites in United States, Bulgaria and 16 more
- Volunteers
- 834 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2 in Obese
TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study
The purpose of this study is to continue to follow participants in the TODAY clinical trial as they transition to non-blinded, non-randomized standard diabetes care and management with monitoring and follow-up for up to 24 months…
- Trial name
- T2P1 (NCT01364350)
- Testing
- standard of care in general clinical practice
- Where
- 16 sites in United States
- Volunteers
- 550 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Hypoglycemia
Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes
The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon counterregulatory response to hypoglycemia in type 1 diabetes.
- Trial name
- NCT01147276
- Testing
- Vildagliptin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Non-Small Cell Lung Cancer, Colorectal Cancer
A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in…
- Conditions
- Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor
- Trial name
- NCT03953235
- Testing
- GRT-C903, GRT-R904, nivolumab
- Where
- 12 sites in United States
- Volunteers
- 39 people
- Sponsor
- Gritstone bio, Inc.
Advanced Hepatocellular Carcinoma
A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
To evaluate the efficacy and safety of cadonilimab combined with regorafenib in patients with HCC who progressed on systemic therapy.
- Trial name
- NCT05773105
- Testing
- Cadonilimab+regorafenib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.